Navigation Links
Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
Date:10/24/2013

  • On October 22, 2013 Shire announced that it had decided to discontinue the construction of its new manufacturing facility in San Diego. Shire will continue to manufacture DERMAGRAFT in its existing facility in La Jolla, and Shire's ability to meet expected future demand for DERMAGRAFT is not impacted by this decision.  Shire is currently assessing possible disposal opportunities in relation to this facility.

  • Share Buy-Back Program

    • In Q4 2012 Shire commenced a share buy-back program, for the purpose of returning funds to shareholders, of up to $500 million, through both direct purchases of Ordinary Shares and through the purchase of Ordinary Shares underlying American Depositary Receipts. As of October 22, 2013 Shire had made on-market repurchases totaling 9,807,835 Ordinary Shares at a cost of $299 million (excluding transaction costs).

    BOARD AND COMMITTEE CHANGES

    • On October 23, 2013 Shire announced that Dominic Blakemore will join the Shire Board of Directors effective January 1, 2014.  On joining the Board, Dominic will become a member of the Shire Audit, Compliance & Risk Committee. Dominic's career experience includes finance and strategy roles with global corporations.  He is currently Group Finance Director of Compass Group plc.

    ADDITIONAL INFORMATION

    The following additional information is included in this press release:

    Page Overview of Third Quarter 2013 Financial Results 6 Financial Information 10 Non GAAP Reconciliation 19 Notes to Editors 23 Safe Harbor Statement 24 Explanation of Non GAAP Measures 24 Trade Marks 25

     

    Dial in details for the live conference call  for investors at 14:00 BST / 09:00 ED
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
    11. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... more than EUR 1.022 billion in 2013; while production volume reached close to ... leading producing country with a share of 75.5% of the region’s total aluminium ...
    (Date:7/28/2015)... ... July 28, 2015 , ... VetStem Biopharma will be ... cell credentialing course to local area veterinarians. , The tour and course will be ... at no charge) at VetStem’s Poway facility. Staff members are welcome to attend with ...
    (Date:7/28/2015)... 2015  Kerastem Technologies announce that the Company has ... Center For Biologics Evaluation and Research (CBER) Office of ... trial investigating the safety and feasibility of the Company,s ... pattern baldness (androgenic alopecia). The phase II ... work in Europe and ...
    (Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
    Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
    ... Milestone Scientific,Inc. (OTC Bulletin Board: MLSS), ... announced that it has acquired additional,patent rights ... rights related to controlling the flow rate ... through issuance of 260,000 shares of,restricted common ...
    ... Approval would make Zevalin only Radioimmunotherapy in U.S. to be ... ... Cell Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced today ... the U.S. Food and Drug,Administration (FDA) for use of Zevalin(R) ...
    ... Oct. 1 TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ) ... for tezampanel with the U.S. Food and Drug Administration ... the Phase II data, the FDA agreed,that TorreyPines may ... The FDA also confirmed that the required thorough QT/QTc ...
    Cached Biology Technology:Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations 2Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 2TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 3TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel 4
    (Date:7/7/2015)... 30, 2015 Research ... addition of the "Capacitive Fingerprint Sensors Patent ... To this date, fingerprint sensing technology is the ... sensors are well developed. This patent landscape focuses ... The domain of capacitive fingerprint sensors is ...
    (Date:7/2/2015)... , July 2, 2015 Fingerprint ... FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World Peace ... of FPC,s distributors in Asia . Deliveries ... The sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of approximately 2,200 ...
    (Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
    Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
    ... of scientists has produced a new type of rice ... other rice crops. Professor Andy Pereira at the Virginia ... India, Indonesia, Israel, Italy, Mexico and The Netherlands to ... as HARDY that improves key features of this important ...
    ... where the Andes meet the Amazon and is locally grown ... the Pacific. It is produced in three species which are ... has resulted in fertile and stable hybrids. This gives it ... quality food production and offer a sustainable cropping system that ...
    ... Recently, researchers at Iowa State University discovered a way ... By zeroing in on early stages leading up to ... predictions across a variety of environmental conditions. The team ... of Crop Science. The Crop Environment Resource Synthesis ...
    Cached Biology News:HARDY rice: less water, more food 2HARDY rice: less water, more food 3Yam bean a nearly forgotten crop 2Simulating kernel production influences maize model accuracy 2
    Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
    Human PLUNC Biotinylated Affinity Purified PAb...
    Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
    ... Rabbit polyclonal to GRASP1 ( ... Antigen: Synthetic ... from the C terminal region of ... hemocyanin (KLH). Entrez ...
    Biology Products: